Ontology highlight
ABSTRACT:
SUBMITTER: Verstovsek S
PROVIDER: S-EPMC3856961 | biostudies-literature | 2013 Dec
REPOSITORIES: biostudies-literature
Verstovsek Srdan S Mesa Ruben A RA Gotlib Jason J Levy Richard S RS Gupta Vikas V DiPersio John F JF Catalano John V JV Deininger Michael W N MW Miller Carole B CB Silver Richard T RT Talpaz Moshe M Winton Elliott F EF Harvey Jimmie H JH Arcasoy Murat O MO Hexner Elizabeth O EO Lyons Roger M RM Paquette Ronald R Raza Azra A Vaddi Kris K Erickson-Viitanen Susan S Sun William W Sandor Victor V Kantarjian Hagop M HM
Haematologica 20130913 12
COMFORT-I is a randomized, double-blind, placebo-controlled trial of the Janus kinase 1/Janus kinase 2 inhibitor ruxolitinib in 309 patients with intermediate-2 or high-risk myelofibrosis. This analysis of COMFORT-I describes the long-term efficacy and safety of ruxolitinib (median follow-up, 2 years). Spleen volume was measured by magnetic resonance imaging, and quality of life was evaluated using the EORTC QLQ-C30. Overall survival was determined according to randomized treatment group. At the ...[more]